JP2020513243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513243A5 JP2020513243A5 JP2019529896A JP2019529896A JP2020513243A5 JP 2020513243 A5 JP2020513243 A5 JP 2020513243A5 JP 2019529896 A JP2019529896 A JP 2019529896A JP 2019529896 A JP2019529896 A JP 2019529896A JP 2020513243 A5 JP2020513243 A5 JP 2020513243A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- cell
- immune cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104666A JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023172588A JP2024001145A (ja) | 2016-12-05 | 2023-10-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430263P | 2016-12-05 | 2016-12-05 | |
| US62/430,263 | 2016-12-05 | ||
| PCT/US2017/064507 WO2018106595A1 (en) | 2016-12-05 | 2017-12-04 | Compositions and methods for immune cell modulation in adoptive immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104666A Division JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513243A JP2020513243A (ja) | 2020-05-14 |
| JP2020513243A5 true JP2020513243A5 (https=) | 2020-08-13 |
| JP7098615B2 JP7098615B2 (ja) | 2022-07-11 |
Family
ID=62491299
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529896A Active JP7098615B2 (ja) | 2016-12-05 | 2017-12-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2022104666A Pending JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023172588A Pending JP2024001145A (ja) | 2016-12-05 | 2023-10-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104666A Pending JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023172588A Pending JP2024001145A (ja) | 2016-12-05 | 2023-10-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11932870B2 (https=) |
| EP (1) | EP3548049A4 (https=) |
| JP (3) | JP7098615B2 (https=) |
| WO (1) | WO2018106595A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| EP3654986A2 (en) * | 2017-07-19 | 2020-05-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| SG11202004384YA (en) | 2017-11-17 | 2020-06-29 | Univ Illinois | Cancer therapy by degrading dual mek signaling |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| JP2022516389A (ja) * | 2018-05-31 | 2022-02-28 | ワシントン・ユニバーシティ | 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
| AU2019336229A1 (en) * | 2018-09-07 | 2021-03-18 | Sotio, LLC | Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof |
| KR20210084442A (ko) * | 2018-10-05 | 2021-07-07 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 포도막 흑색종 치료를 위한 병용 요법 |
| EP3874024A1 (en) | 2018-10-31 | 2021-09-08 | Juno Therapeutics GmbH | Methods for selection and stimulation of cells and apparatus for same |
| SG11202104287RA (en) * | 2018-11-06 | 2021-05-28 | Univ Washington | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| CN110157680A (zh) * | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| CN112300997A (zh) * | 2019-08-01 | 2021-02-02 | 上海赛比曼生物科技有限公司 | 通用型car-t细胞及其制备和应用 |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| JP2022554217A (ja) * | 2019-10-23 | 2022-12-28 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 養子免疫療法 |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| JP2024503044A (ja) * | 2021-01-12 | 2024-01-24 | ザ スクリプス リサーチ インスティテュート | Ｔ細胞の抗腫瘍免疫を再プログラミングするための小分子 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| US20230355678A1 (en) * | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| EP4636093A1 (en) * | 2024-04-19 | 2025-10-22 | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel | Targeting mapk-erk pathway for enhancing nucleic acid delivery |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92382A (en) | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| AU770867B2 (en) | 1999-08-13 | 2004-03-04 | Fumie Sato | Prostaglandin derivatives |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040175373A1 (en) | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050075276A1 (en) | 2003-03-14 | 2005-04-07 | Christopher Rudd | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| WO2007103901A2 (en) | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| BRPI0714409A2 (pt) | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
| EP2094837B1 (en) | 2006-12-14 | 2012-04-25 | Medical Research Council | Use of pi3k, m-tor and akt inhibitors to induce foxp3 expression and generate regulatory t cells |
| SG188904A1 (en) | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| EP4585589A3 (en) | 2008-12-03 | 2025-11-19 | The Scripps Research Institute | Stem cell cultures |
| CN102281761A (zh) | 2009-01-14 | 2011-12-14 | 健康研究股份有限公司 | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| SI3151672T1 (sl) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| ES2771926T3 (es) * | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US20180112180A1 (en) | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2018509459A (ja) | 2015-03-27 | 2018-04-05 | ナントクエスト インコーポレイテッド | がん治療薬との併用療法におけるｎｋ−９２細胞 |
| WO2016179283A1 (en) | 2015-05-05 | 2016-11-10 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| PT3294764T (pt) | 2015-05-15 | 2021-02-15 | Hope City | Composições de recetores de antigénios quiméricos |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3068604A1 (en) | 2017-06-13 | 2018-12-20 | Fate Therapeutics, Inc. | Compositions and methods for inducing myeloid suppressive cells and use thereof |
-
2017
- 2017-12-04 WO PCT/US2017/064507 patent/WO2018106595A1/en not_active Ceased
- 2017-12-04 JP JP2019529896A patent/JP7098615B2/ja active Active
- 2017-12-04 US US16/466,265 patent/US11932870B2/en active Active
- 2017-12-04 EP EP17879179.4A patent/EP3548049A4/en active Pending
-
2022
- 2022-06-29 JP JP2022104666A patent/JP2022130607A/ja active Pending
-
2023
- 2023-10-04 JP JP2023172588A patent/JP2024001145A/ja active Pending
-
2024
- 2024-02-14 US US18/441,709 patent/US20240263135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513243A5 (https=) | ||
| US20250215396A1 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| US20240263135A1 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| US20220401487A1 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| CN109415699B (zh) | Cd4cd8双阳性t细胞的制备方法 | |
| JP2024123210A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP2022078215A (ja) | 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法 | |
| JP7668781B2 (ja) | 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法 | |
| AU2016344779A1 (en) | Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells | |
| CN119256076A (zh) | 用于产生调节性t细胞的方法 | |
| WO2022059780A1 (ja) | ｉＰＳ細胞を介する再生Ｔ細胞の製造方法 | |
| HK40092133A (zh) | 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法 | |
| Ma | Derivation of Lymphocytes from Human induced Pluripotent Stem Cells |